Neurologist recommended5**

 Targeted Nutrition to Slow Cognitive Decline and Brain Shrinkage1,3 

Improve Brain Health, Memory, Focus & Concentration

shop now

Cerefolin Brain Wellness® is a medical food for the clinical dietary management of mild cognitive impairment with hyperhomocysteinemia and is specially formulated to meet the distinctive nutritional requirements for this condition. Use under medical supervision.

 When Little Slips Start Adding Up 

Everyone forgets things now and then — a name, a date, where you left your keys. But when those slips start to happen more often, or daily life feels a little harder, it might be worth bringing up with your healthcare provider. Some additional signs you may notice include:

  • check_circle

    Missing appointments often

  • check_circle

    Struggling to find words

  • check_circle

    Frequently losing things

  • check_circle

    Losing train of thought

  • check_circle

    Having trouble deciding

  • check_circle

    Getting lost in familiar places

     Dual Action Formula 

    Targeted nutrition for Mild Cognitive Impairment (MCI) with elevated homocysteine levels

     Improves 

    Cerefolin Brain Wellness® helps support overall brain function by providing essential nutrients that aid in reducing harmful homocysteine levels, which can negatively impact brain health.3*

    Individuals taking Cerefolin Brain Wellness® showed improvement in memory and ability to focus on daily activities.4*

    Cerefolin Brain Wellness® helped people maintain attention and stay on task, which are essential for completing daily tasks and decision-making processes.4*

     Slows 

    Long-term use of Cerefolin Brain Wellness® was associated with a significantly slower rate of cognitive decline, especially in individuals with mild cognitive impairment.2*

    Research shows that people with mild cognitive impairment (MCI) and elevated homocysteine who took Cerefolin Brain Wellness® experienced slower brain shrinkage — helping support memory, thinking skills, and overall brain health.1*

    Trust in the Results

    Neurologists recommend Cerefolin Brain Wellness®*. Starting early can help protect your brain cells, slow the loss of brain function, and improve your overall quality of life.1-3

    You may start seeing improvements in as little as 45days

    • Many saw improvement inmood, memory, work lifebalance, and energy levels

    • Many saw improvement inquality of life and ability to learn,remember and understand3-4

    • Many continue to experienceimprovements in memory andcognitive function

       What people are saying§||*Individual results may vary. 

      • "I'm very appreciative of yourwonderful service and also yourgreat product." "I recommend itto everybody."

        -Tressie

      • "Those things really work." "I'mnot going to the refrigeratorlooking for ketchup andforgetting what I went to it for."

        - George

      • "I believe that CerefolinNAC*helped me tremendously withmy day to day thinking."

        -Monica

      • "I am feeling improvementsfrom taking CerefolinNAC*.""We have many good yearsahead of us to enjoy the activelives we lead."

        -Tessa

      • "This has been a night and daydifference. I feel like myselfagain."

        -Roland

      • "I am doing much better."

        - Laura

      • "I used to forget things a lot, butstill a little, but not like before.Before it was terrible. I wouldeven cry. I would get frustratedbecause my forgetfulness wasso bad."

        -Cecelia

         References 

        1. Shankle WR, et al. J Alzheimers Dis. 2016;54(3):1073-1084.
        2. Shankle WR, et al. J Aging Res Clin Pract. 2013;2.
        3. Hara J, et al. Nutr Health Aging. 2015;19.
        4. Alfasigma USA, Inc. PLUS Program patient survey results. Data on file. 2012.
        5. Alfasigma USA, Inc. Support data. Data on file. 2019-2024.
        6. Chan A, Shea TB. J Nutr Health Aging. 2008;12(4):252-261.
        7. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Int J Geriatr Psychiatry. 2012;27(6):592-600.
        8. Merrill E, Laughlin GA, Barrett-Connor E. Am J Epidemiol. 2005;162(7):644-653.
        9. Reynolds EH. BMJ. 2000;320(7248):1512-1515.
        10. de Jager CA, Refsum H, Smith AD. Neurobiol Aging. 2014;35(suppl 2):S35-S39.
        11. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. Curr Opin Pharmacol. 2007;7(4):355-359.
        12. Kelly GS. Altern Med Rev. 2000;5(6):467-471.
        13. Antoniades C, Shirodaria C, Warrick N, et al. Circulation. 2006;114(11):1193-1201.
        14. Calderón-Ospina CA, Nava-Mesa MO. CNS Neurosci Ther. 2020;26(1):5-18.
        15. Sah RP, et al. Ann Geriatr Med Res. 2023;27(4):370-380.
        16. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Arch Neurol. 2003;60(1):59-64.
        17. Smith AD, Refsum H. J Alzheimers Dis. 2016;54(4):1149-1166.
        18. Seshadri S, Beiser A, Selhub J, et al. N Engl J Med. 2002;346(7):476-483.
        19. Yao Y, Wang J, Wang J, et al. J Geriatr Cardiol. 2017;14(1):49-55.
        20. Diaz-Arrastia R. Arch Neurol. 2000;57(10):1422-1428.
        21. Keller AC, Kane MA, Heinze-Milne S, et al. J Appl Physiol. 2019;126(2):379-387.
        22. Zhu Y, Liu J, Wang Y, et al. Climacteric. 2020;23(3):274-281.
        23. Estrada DA, Ismail-Beigi F. Am J Hematol. 2001;67(3):221-227.
        24. Luzzi S, D’Agostino V, Orlandi A, et al. Biomedicines. 2022;10(8):1892.
        25. Diekman MJ, Anghelescu N, Endert E. Clin Endocrinol (Oxf). 2001;54(5):631-636.
        26. Paknahad Z, Chitsaz A. Int J Prev Med. 2012;3(9):633-640.
        27. DeSouza C, Keaney JF Jr. Drugs. 2002;62(12):1657-1670.
        28. Myles PS, Leslie K, McNeil J, Forbes A, Chan MTV. Br J Anaesth. 2008;100(5):635-643.
        29. Fallah S, Nouroozi V, Seifi M, Samadikuchaksaraei A. J Clin Lab Anal. 2012;26(5):360-365.
        30. Lerman LO, Chade AR. Am J Physiol Heart Circ Physiol. 2022;322(4):H709-H720.
        31. Troen AM, Shea-Budgell MA, Shukitt-Hale B, et al. Proc Natl Acad Sci U S A. 2008;105(34):12474-12479.
        32. Hajj Mouhamed D, Ezzaher A, Neffati F, et al. Clin Chem Lab Med. 2011;49(6):987-993.
        33. Smith AD, Smith SM, de Jager CA, et al. PLoS One. 2010;5(9):e12244.
        34. Douaud G, Refsum H, de Jager CA, et al. Proc Natl Acad Sci U S A. 2013;110(23):9523-9528.
        35. Xu M, Zhang Y, Liu Y, et al. Nutr Neurosci. 2023;26(6):417-430.
        36. Sohouli MH, et al. Nutr Rev. 2023;82(6):726-737.